Low-dose chemotherapy for canine appendicular osteosarcoma

• Published in: Journal of Japan Veterinary Cancer Society Vol. 2; no. 1; pp. 1 - 6
• Main Authors: Shida, Takuo, Fujii, Takashi, Kawamura, Hiroko, Yamada, Toru, Takeda, Haruo, Maruo, Takuya, Imai, Rie, Ito, Tetsuro, Madarame, Hiroo, Kayanuma, Hideki, Suganuma, Tsunenori
• Format: Journal Article
• Language: Japanese; English
• Published: Japan Veterinary Cancer Society 2011
• Subjects: amputation; appendicular osteosarcoma; canine; carboplatin; low-dose chemotherapy
• ISSN: 1884-3344; 1884-3352
• DOI: 10.12951/jvcs.2010-004

Objectives: The objective of this study was to describe the efficacy and safety of low-dose chemotherapy(≤50% of standard dose)for canine osteosarcoma. Methods: Canine osteosarcoma treated with amputation and low-dose cisplatin or carboplatin(i.e., cisplatin ≤35 mg/m2, carboplatin ≤150 mg/m2)as adjuvant chemotherapy was investigated. Dogs with limb amputation and adjuvant chemotherapy(adjuvant chemotherapy group, n=10(cisplatin, n=3; carboplatin, n=7))were compared to dogs receiving no treatment(no-treatment group, n=5)or limb amputation alone(surgery-alone group, n=5)in the same period. Results: For cisplatin, the median dose was 25 mg/m2, median number of treatments was 12, and median interval was 3 weeks. For carboplatin, the median dose was 100 mg/m2, median number of doses was 11, and median treatment interval was 3 weeks. Most clinical and hematological abnormalities were mild or moderate. Median survival times for the no-treatment group, surgery-alone group, and adjuvant chemotherapy group were 84 days, 60 days, and 317 days, respectively. The adjuvant chemotherapy group showed significantly increased survival compared to the no-treatment and surgery-alone groups(P<0.05, P=0.023). Clinical Significance: Low-dose cisplatin or carboplatin chemotherapy may improve outcomes for cases of canine osteosarcoma with limb amputation.